IRD

3.9902.21%
JK

Joseph K. Schachle

Chief Operating Officer

Mr. Joseph K. Schachle, also known as Joe, MBA, serves as Chief Operating Officer of Ocuphire Pharma, Inc. since November 27, 2023. He was also a Chief Operating Officer at Opus Genetics Inc. until November 2023. He has been the Chief Operating Officer of Parion Sciences, Inc. since June 2, 2014. Mr. Schachle has been Executive Vice President of Pulmonary Business at Inspire Pharmaceuticals, Inc. since July 2010. He joined Parion from Grifols where he served as Head of Global Marketing Operations. Mr. Schachle served as Executive Vice President of Inspire Pharmaceuticals Inc. since February 20, 2007 and served as its Chief of Commercial and Corporate Operations since August 2007. Mr. Schachle served as Chief of Commercial Operations of Inspire Pharmaceuticals Inc. from February 20, 2007 to August 2007. Mr. Schachle served as Senior Vice President of Marketing and Sales of Inspire Pharmaceuticals Inc., from January 2004 to February 20, 2007 and served as its Vice President of Marketing and Sales from February 2003 to January 2004. Mr. Schachle initially joined Inspire in 2001. He was responsible for the development of a marketing and sales infrastructure in North America to commercialize potential products from Inspire Pharmaceuticals Inc.'s pipeline, as well as partnered products. He serves as Director at The Council for Entrepreneurial Development. He has extensive experience in pharmaceutical marketing and sales, and has had responsibility for the successful launch of major new products including the marketing of Glaxo SmithKline's Advair. His experience includes marketing and sales positions of significant responsibility at The Upjohn Company, Inspire and MedImmune. From June 1998 to April 2001, Mr. Schachle served as Director, Marketing for GlaxoSmithKline. He served as Director of Marketing for infectious disease products at MedImmune from April 2002 to January 2003, where he was responsible for strategic brand management and promotion of Synagis®, MedImmune’s largest product, and Cytogam®. In his previous role at Inspire from April 2001 to April 2002, Mr. Schachle was responsible for the new product planning and market research that laid the groundwork for the commercialization of diquafosol tetrasodium (INS365), the first potential product from Inspire’s pipeline. Mr. Schachle holds a BBA in Marketing from James Madison University and an MBA from Old Dominion University.

Positions